• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人类类器官模型中严重急性呼吸综合征相关冠状病毒2发病机制的研究综述。

Review of studies of severe acute respiratory syndrome related coronavirus-2 pathogenesis in human organoid models.

作者信息

Egilmezer Ece, Rawlinson William D

机构信息

Serology and Virology Division, NSW Health Pathology, Prince of Wales Hospital, Sydney, Australia.

School of Medical Sciences, University of New South Wales, Sydney, Australia.

出版信息

Rev Med Virol. 2021 Nov;31(6):e2227. doi: 10.1002/rmv.2227. Epub 2021 Mar 25.

DOI:10.1002/rmv.2227
PMID:33763936
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8250302/
Abstract

Severe acute respiratory syndrome related coronavirus-2 (SARS-CoV-2) is the cause of Covid-19 which was classified as a global pandemic in March 2020. The increasing global health and economic burden of SARS-CoV-2 has necessitated urgent investigations into the pathogenesis of disease and development of therapeutic and vaccination regimens. Human trials of vaccine and antiviral candidates have been undertaken, but basic pathogenetic studies are still required to inform these trials. Gaps in understanding of cellular infection by, and immunity to, SARS-CoV-2 mean additional models are required to assist in improved design of these therapeutics. Human organoids are three-dimensional models that contain multiple cell types and mimic human organs in ex vivo culture conditions. The SARS-CoV-2 virus has been implicated in causing not only respiratory injury but also injury to other organs such as the brain, liver and kidneys. Consequently, a variety of different organoid models have been employed to investigate the pathogenic mechanisms of disease due to SARS-CoV-2. Data on these models have not been systematically assembled. In this review, we highlight key findings from studies that have utilised different human organoid types to investigate the expression of SARS-CoV-2 receptors, permissiveness, immune response, dysregulation of cellular functions, and potential antiviral therapeutics.

摘要

严重急性呼吸综合征相关冠状病毒2(SARS-CoV-2)是导致2019冠状病毒病(Covid-19)的病原体,该病于2020年3月被列为全球大流行疾病。SARS-CoV-2给全球健康和经济带来的负担日益加重,因此迫切需要对该疾病的发病机制以及治疗和疫苗接种方案的研发展开研究。目前已开展了疫苗和抗病毒候选药物的人体试验,但仍需要基础发病机制研究为这些试验提供依据。对SARS-CoV-2细胞感染和免疫的认识存在差距,这意味着需要更多模型来辅助改进这些疗法的设计。人源类器官是包含多种细胞类型的三维模型,可在体外培养条件下模拟人体器官。SARS-CoV-2病毒不仅会导致肺部损伤,还会损伤大脑、肝脏和肾脏等其他器官。因此,人们采用了多种不同的类器官模型来研究SARS-CoV-2所致疾病的发病机制。尚未对这些模型的数据进行系统整理。在本综述中,我们重点介绍了利用不同类型人源类器官研究SARS-CoV-2受体表达、易感性、免疫反应、细胞功能失调及潜在抗病毒疗法的研究中的关键发现。

相似文献

1
Review of studies of severe acute respiratory syndrome related coronavirus-2 pathogenesis in human organoid models.人类类器官模型中严重急性呼吸综合征相关冠状病毒2发病机制的研究综述。
Rev Med Virol. 2021 Nov;31(6):e2227. doi: 10.1002/rmv.2227. Epub 2021 Mar 25.
2
ACE2-Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants.靶向ACE2的抗体可抑制新冠病毒奥密克戎和德尔塔变种。
Signal Transduct Target Ther. 2022 Feb 9;7(1):43. doi: 10.1038/s41392-022-00913-3.
3
Severe acute respiratory syndrome-coronavirus-2: Current advances in therapeutic targets and drug development.严重急性呼吸系统综合征冠状病毒 2:治疗靶点和药物研发的最新进展。
Rev Med Virol. 2021 May;31(3):e2174. doi: 10.1002/rmv.2174. Epub 2020 Sep 23.
4
SARS-CoV-2 multifaceted interaction with the human host. Part II: Innate immunity response, immunopathology, and epigenetics.SARS-CoV-2 与人类宿主的多方面相互作用。第二部分:先天免疫反应、免疫病理学和表观遗传学。
IUBMB Life. 2020 Nov;72(11):2331-2354. doi: 10.1002/iub.2379. Epub 2020 Sep 16.
5
An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.贝塔冠状病毒病毒进入抑制剂的最新综述:从过去的发现中吸取教训,推进 COVID-19 药物发现。
Curr Top Med Chem. 2021;21(7):571-596. doi: 10.2174/1568026621666210119111409.
6
Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry.基于纳米荧光素酶互补的生物报告基因揭示了SARS-CoV-2刺突蛋白N-糖基化对病毒进入的重要性。
Mol Ther. 2021 Jun 2;29(6):1984-2000. doi: 10.1016/j.ymthe.2021.02.007. Epub 2021 Feb 10.
7
Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route.野生型小鼠感染 SARS-CoV-2 B.1.351 变异株提示可能存在新的跨种传播途径。
Signal Transduct Target Ther. 2021 Dec 14;6(1):420. doi: 10.1038/s41392-021-00848-1.
8
The role of microRNAs in modulating SARS-CoV-2 infection in human cells: a systematic review.microRNAs 在调节人类细胞中 SARS-CoV-2 感染中的作用:系统评价。
Infect Genet Evol. 2021 Jul;91:104832. doi: 10.1016/j.meegid.2021.104832. Epub 2021 Apr 1.
9
The OM-85 bacterial lysate inhibits SARS-CoV-2 infection of epithelial cells by downregulating SARS-CoV-2 receptor expression.OM-85 细菌裂解物通过下调 SARS-CoV-2 受体表达来抑制上皮细胞中的 SARS-CoV-2 感染。
J Allergy Clin Immunol. 2022 Mar;149(3):923-933.e6. doi: 10.1016/j.jaci.2021.11.019. Epub 2021 Dec 10.
10
Covid-19 and kidney injury: Pathophysiology and molecular mechanisms.Covid-19 与肾脏损伤:病理生理学与分子机制。
Rev Med Virol. 2021 May;31(3):e2176. doi: 10.1002/rmv.2176. Epub 2020 Oct 6.

引用本文的文献

1
Human cytomegalovirus (CMV) dysregulates neurodevelopmental pathways in cerebral organoids.人类巨细胞病毒(CMV)扰乱脑类器官中的神经发育途径。
Commun Biol. 2024 Mar 19;7(1):340. doi: 10.1038/s42003-024-05923-1.
2
Study on the potential of Sanghuangporus sanghuang and its components as COVID-19 spike protein receptor binding domain inhibitors.桑黄及其成分作为 COVID-19 刺突蛋白受体结合域抑制剂的潜力研究。
Biomed Pharmacother. 2022 Sep;153:113434. doi: 10.1016/j.biopha.2022.113434. Epub 2022 Jul 18.
3
3D Human Organoids: The Next "Viral" Model for the Molecular Basis of Infectious Diseases.3D人体类器官:传染病分子基础的下一个“热门”模型。
Biomedicines. 2022 Jun 28;10(7):1541. doi: 10.3390/biomedicines10071541.
4
Human Brain Organoids as Models for Central Nervous System Viral Infection.人脑类器官作为中枢神经系统病毒感染的模型
Viruses. 2022 Mar 18;14(3):634. doi: 10.3390/v14030634.
5
An Adverse Outcomes Approach to Study the Effects of SARS-CoV-2 in 3D Organoid Models.一种利用不良结局方法研究 SARS-CoV-2 在 3D 类器官模型中作用的研究方法。
J Mol Biol. 2022 Feb 15;434(3):167213. doi: 10.1016/j.jmb.2021.167213. Epub 2021 Aug 23.

本文引用的文献

1
SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery.用于新冠病毒疾病建模和药物发现的原代人肺上皮细胞的严重急性呼吸综合征冠状病毒2感染
Cell Rep. 2021 May 4;35(5):109055. doi: 10.1016/j.celrep.2021.109055. Epub 2021 Apr 13.
2
The scRNA-seq Expression Profiling of the Receptor ACE2 and the Cellular Protease TMPRSS2 Reveals Human Organs Susceptible to SARS-CoV-2 Infection.单细胞 RNA 测序表达谱分析受体 ACE2 和细胞蛋白酶 TMPRSS2,揭示了人类易感染 SARS-CoV-2 的器官。
Int J Environ Res Public Health. 2021 Jan 2;18(1):284. doi: 10.3390/ijerph18010284.
3
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
4
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.巴瑞替尼联合瑞德西韦治疗住院的新冠成年患者
N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11.
5
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
6
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.用于治疗新冠肺炎的抗病毒药物 repurposed - 世界卫生组织团结试验中期结果
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
7
Progenitor identification and SARS-CoV-2 infection in human distal lung organoids.人远端肺类器官中的祖细胞鉴定和 SARS-CoV-2 感染。
Nature. 2020 Dec;588(7839):670-675. doi: 10.1038/s41586-020-3014-1. Epub 2020 Nov 25.
8
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.吸入用干扰素 β-1a(SNG001)治疗 SARS-CoV-2 感染的安全性和有效性:一项随机、双盲、安慰剂对照、2 期临床试验。
Lancet Respir Med. 2021 Feb;9(2):196-206. doi: 10.1016/S2213-2600(20)30511-7. Epub 2020 Nov 12.
9
Identification of SARS-CoV-2 inhibitors using lung and colonic organoids.使用肺和结肠类器官鉴定 SARS-CoV-2 抑制剂。
Nature. 2021 Jan;589(7841):270-275. doi: 10.1038/s41586-020-2901-9. Epub 2020 Oct 28.
10
Comparing Clinical Characteristics of Influenza and Common Coronavirus Infections Using Electronic Health Records.利用电子健康记录比较流感和常见冠状病毒感染的临床特征。
J Infect Dis. 2021 Jun 4;223(11):1879-1886. doi: 10.1093/infdis/jiaa626.